Compare VICI & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VICI | INSM |
|---|---|---|
| Founded | 2016 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3B | 22.4B |
| IPO Year | 2017 | 2000 |
| Metric | VICI | INSM |
|---|---|---|
| Price | $23.51 | $118.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 24 |
| Target Price | $33.75 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 6.9M | 1.8M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.29% | N/A |
| EPS Growth | ★ 1.95 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $4,006,116,000.00 | N/A |
| Revenue This Year | $4.47 | $182.31 |
| Revenue Next Year | $1.67 | $65.19 |
| P/E Ratio | $17.90 | ★ N/A |
| Revenue Growth | ★ 4.08 | N/A |
| 52 Week Low | $23.18 | $90.39 |
| 52 Week High | $33.01 | $212.75 |
| Indicator | VICI | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 28.82 | 44.20 |
| Support Level | N/A | $97.66 |
| Resistance Level | $27.45 | $119.54 |
| Average True Range (ATR) | 0.35 | 5.39 |
| MACD | -0.11 | -1.02 |
| Stochastic Oscillator | 14.08 | 13.84 |
VICI Properties Inc is a real estate investment trust based in the United States. It engaged in the business of owning and acquiring gaming, hospitality, wellness, entertainment and leisure destinations, subject to long-term triple net leases. It own nearly 93 experiential assets across a geographically portfolio consisting of nearly 54 gaming properties and nearly 39 other experiential properties across the United States and Canada, including Caesars Palace Las Vegas, MGM Grand and the Venetian Resort Las Vegas.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.